Summary
A cost-effectiveness analysis of the Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Therapy (OMT) Versus OMT [FAME 2] trial indicates that FFR-guided PCI is economically viable. The initial cost of FFR-guided PCI is higher than that of medical therapy, but the cost gap narrows by >50% at 1 year.
- Cardiology Clinical Trials
- Interventional Techniques & Devices
- Coronary Artery Disease
- © 2012 MD Conference Express®